(Q28217724)

https://api.crossref.org/works/10.1517/14656566.6.1.3

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.6.1.3

Effect of clopidogrel on bleeding after coronary artery bypass surgery

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.6.1.3

Late stent thrombosis after implantation of a sirolimus‐eluting stent

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14656566.6.1.3

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A comparison of short- and long-term outcomes for balloon angioplasty and coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Platelets and anti-platelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Subacute stent thrombosis: evolving issues and current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Enhancement of platelet inhibition of ticlopidine plus aspirin vs aspirin alone given prior to elective PTCA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Thrombotic thrombocytopenic purpura related to ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Drug eluting coronary stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Drug-eluting stents in vascular intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Drug-eluting stents: an early systematic review to inform policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3

ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.3